Indeed, results of animal and human intervention studies suggest that an attenuation of the development of MASLD and/or improvement of the disease is often afflicted with a lowering of Tnfa mRNA expression in liver tissue or circulating TNFα protein levels in blood [37,38]. Here, TNF is linked to metabolic dysfunction-associated steatotic liver disease.